Check out your Company Bowl for anonymous work chats.
#HappyNewYear from Amplity Health! We wish you a year filled with success, good health, and meaningful accomplishments. What are you most looking forward to in 2024?
While each rare disease is unique, rare disease patients often have one thing in common: an extensive timeline before reaching a diagnosis. Amplity Insights' blog discusses how pharma and biotech companies are catching patients earlier in their treatment journey:
The industry is witnessing a pivotal moment with the loss of exclusivity for adalimumab, marking the largest event of its kind. Several adalimumab biosimilars have entered the market, and more are expected to follow. As competition intensifies, PBMs and manufacturers must strategically position themselves in the market. Amplity's Nikolina Janakievski, Associate Director and Lead Strategist, Market Access, co-published this article for Life Science Leader to delve into the strategies necessary to navigate this evolving landscape, demonstrating how Amplity's market access team is equipped to provide the creative strategy and predictive analytics necessary to execute a successful biosimilar launch. Visit https://lnkd.in/ebq6PcnS to read a copy of the Life Science Leader article.
We're committed to empowering your teams with the knowledge and skills they need to excel. With over 40 years of dedicated service, Amplity Learning Solutions is a trusted partner to global pharma companies. Our extensive experience and expertise allow us to provide tailor-made learning and development solutions for pharma’s Clinical and Medical, Commercial, and Medical Communications teams. Contact us to learn how we can work together to unlock the full potential of your teams.
We are honored to share that AskX, our customized implementation of generative #AI, has been named one of the Most Interesting Innovations of 2023 by PM360 Magazine. Developed by the Amplity Insights team, AskX revolutionizes real-world evidence generation and #medical and #commercial field operations; empowers researchers, brand leaders, and field operations managers to interrogate Amplity Health’s Insights database; and more. According to Joseph Turner, Head of Amplity Insights, “The fact that PM360 has selected AskX as an innovator in the Artificial Intelligence category for 2023 emphasizes the game-changing nature of this solution. We’re truly excited to receive this honor.” Read more about AskX and the PM360 award in the press release: https://bit.ly/3TpzQZT #PM360InnovationsIssue
Whether you’re pre-launch or already on the market, we always recommend our pharma clients develop and nurture relationships with appropriate thought leaders. Reach out to us when you’re ready to discuss how we develop brand champions by identifying, building, and harnessing productive relationships with thought leaders through advisory boards, workshops, content creation, and conference engagements.
We are honored to share that AskX, our customized implementation of generative #AI, has been named one of the Most Interesting Innovations of 2023 by PM360 Magazine. Developed by the Amplity Insights team, AskX revolutionizes real-world evidence generation and #medical and #commercial field operations; empowers researchers, brand leaders, and field operations managers to interrogate Amplity Health’s Insights database; and more. According to Joseph Turner, Head of Amplity Insights, “The fact that PM360 has selected AskX as an innovator in the Artificial Intelligence category for 2023 emphasizes the game-changing nature of this solution. We’re truly excited to receive this honor.” Read more about AskX and the PM360 award in the press release: https://bit.ly/3TpzQZT hashtag#PM360InnovationsIssue
Amplity’s Commercial Solutions professionals drive uptake of pharmaceutical products through personal and nonpersonal channels. We deliver peak brand performance by first developing scientific understanding and relative value to influence today’s interwoven web of decision-makers. Contact Christina DiBiase, Head of Commercial Solutions, to discuss how to customize your outsourced commercial program.
Research reveals that ~64% of potentially eligible patients are not benefiting from precision oncology therapies. As a solutions provider committed to improving the landscape of personalized medicine, we recognize the urgency of addressing clinical practice gaps. Visit https://lnkd.in/e3Vc2zUF to read our article which details the challenges pharmaceutical companies commonly face when integrating predictive biomarker testing into clinical care.
Patients, HCPs, manufacturers, and payers are all negatively impacted by low patient engagement. Through our partnership with Viver Health LLC, we’re able to offer solutions that blend evidence-based clinical and holistic interventions to improve patient experiences and health outcomes. Contact Stephen Solano or Victoria Barghout for more information.
